Disease modification and Parkinson’s disease: Clinical trial design and population selection • 2025 MDS Congress

There have been nearly 30 years of disease modifying trials for PD, but little success. Prof. Tanya Simuni breaks down clinical trial design for a heterogenous disease like PD and discusses the future goals and importance of a biological definition.